However, the phase III COMBI‐i trial evaluated spartalizumab plus dabrafenib and trametinib for BRAF V600‐mutant melanoma, the results of which showed that the addition of spartalizumab to targeted therapy with dabrafenib and trametinib did not significantly prolong PFS but increased grade ≥3 adverse events by 22% compared with the dabrafenib plus dabrafenib group.309. Here, BRAF is linked to melanoma.